FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

15 letters match. Newest first.

  1. Stephen J. Fallon, Ph.D.

    FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

    High risk
  2. Jose M. Carpio, M.D.

    FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

    Medium
  3. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  4. ExThera Medical Corporation

    ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.

    High risk
  5. United Health Products, Inc.

    FDA warns United Health Products over unapproved significant-risk study of CelluSTAT absorbable hemostat and trial oversight failures.

    High risk
  6. Armstrong County Memorial Hospital

    FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.

    Medium
  7. Louisiana State University Health Science Center IRB

    FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.

    Medium
  8. Massachusetts Institute of Technology MIT

    FDA says MIT's review board for human research failed to make sure consent forms and meeting records met federal rules.

    Medium
  9. New York State Psychiatric Institute IRB

    FDA warned New York State Psychiatric Institute's review board it failed to report serious research problems and reviewed drug studies without required nonscientific member.

    High risk
  10. Nobles Medical Technology II, Inc.

    FDA warns Nobles Medical Technology II over oversight failures in NobleStitch EL clinical study.

    High risk
  11. Jeffrey W. Taub, M.D./Children's Hospital of Michigan

    FDA warns Detroit investigator over pediatric drug trial protocol deviations and lapsed IRB approval.

    High risk
  12. Larkin Community Hospital Institutional Review Board

    Larkin Community Hospital IRB cited for approving trials without required nonscientist member and incomplete records.

    Medium
  13. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  14. Sabine S. Hazan, M.D.

    FDA warned Dr. Sabine Hazan that she enrolled and gave investigational drugs to subjects while IRB (ethics board) approval had lapsed.

    High risk
  15. KDunn and Associates, P.A. dba HealthQuilt

    Houston research sponsor ran a COVID-19 drug study on people without an FDA-approved application or proper consent forms.

    High risk